logo
CMB.TECH's update on the Golden Ocean merger process

CMB.TECH's update on the Golden Ocean merger process

Associated Press4 hours ago
Antwerp, Aug. 11, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext Brussels: CMBT) ('CMB.TECH') provides an additional market update on the progress of the contemplated stock-for-stock merger between CMB.TECH and Golden Ocean Group Limited (NASDAQ: GOGL & Euronext Oslo Børs: GOGL) ('Golden Ocean').
The transaction is structured as a stock-for-stock merger, with Golden Ocean merging with and into CMB.TECH Bermuda Ltd. ('CMB.TECH Bermuda'), a wholly-owned subsidiary of CMB.TECH, with CMB.TECH Bermuda as the surviving company (the 'Merger'). In the framework of the Merger, all outstanding common shares of Golden Ocean [1] will ultimately be exchanged for newly issued CMB.TECH ordinary shares at an exchange ratio of 0.95 ordinary shares of CMB.TECH for each common share of Golden Ocean (the 'Exchange Ratio'), subject to customary adjustments pursuant to the agreement and plan of merger dated 28 May 2025 (the 'Merger Agreement'). Upon closing of the Merger, CMB.TECH would issue approximately 95,952,934 new ordinary shares, assuming the Exchange Ratio is not adjusted.
CMB.TECH notes that the notice by Golden Ocean to hold a special general meeting on 19 August 2025 at 9.00 am ADT, at Hamilton Princess and Beach Club, 76 Pitts Bay Road, Hamilton HM 08, Bermuda, to vote on, among other things, the approval of the Merger Agreement, the Bermuda Merger Agreement (as defined in the Merger Agreement) and the transactions contemplated thereby including the Merger and the appointment of the exchange agent (the 'Golden Ocean SGM'), is available on Golden Ocean's website: GOGL – Notice of Special General Meeting – Golden Ocean. Golden Ocean shareholders of record at the close of business on the record date (16 July 2025) will be entitled to vote at the Golden Ocean SGM.
Subject to a positive outcome of the Golden Ocean SGM, approval of the secondary listing on Euronext Oslo Børs and timely fulfillment of the Merger closing conditions set forth in the Merger Agreement, such as the Golden Ocean refinancing, which is progressing, the parties intend to complete the Merger as soon as possible after the Golden Ocean SGM. The parties currently expect closing to take place on or around 20 August 2025, which would also be the first day of trading for the newly issued shares on NYSE, Euronext Brussels and, tentatively, the first day of trading of CMB.TECH on Euronext Oslo Børs. The day prior to the closing date would be the last day of trading of Golden Ocean's common shares on Nasdaq and on Euronext Oslo Børs.
More information can be found in the registration statement on Form F-4 (the 'Registration Statement') filed by CMB.TECH with the U.S. Securities and Exchange Commission on 1 July 2025, which was declared effective by the SEC on 16 July 2025.
CMB.TECH understands that Golden Ocean has received customary demand letters for additional disclosure in relation to the Registration Statement, as well as correspondence from certain shareholders stating their intention to exercise their rights as dissenting shareholders under Bermuda law, and notes that related legal proceedings have been filed. CMB.TECH and Golden Ocean will analyse these claims and address them appropriately.
[1] Other than Golden Ocean common shares already owned (directly or indirectly) by CMB.TECH or Golden Ocean.
About CMB.TECH
CMB.TECH is a diversified and future-proof maritime group that owns and operates more than 160 seagoing vessels: crude oil tankers, dry bulk vessels, container ships, chemical tankers, offshore wind vessels and workboats. CMB.TECH also offers hydrogen and ammonia fuel to customers, through own production or third-party producers.
CMB.TECH is headquartered in Antwerp, Belgium, and has offices across Europe, Asia, United States and Africa.
CMB.TECH is listed on Euronext Brussels and the NYSE under the ticker symbol 'CMBT'.
About Golden Ocean
Golden Ocean is a Bermuda incorporated shipping company specialising in the transportation of dry bulk cargoes. As of May 2025, the Golden Ocean fleet consists of more than 90 vessels, with an aggregate capacity of approximately 13.7 million deadweight tonnes. Golden Ocean's ordinary shares are listed on Nasdaq with a secondary listing on the Euronext Oslo Børs under the ticker symbol 'GOGL'.
Forward-Looking Statements
Matters discussed in this press release may constitute forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, which provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. CMB.TECH desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words 'believe', 'anticipate', 'intends', 'estimate', 'forecast', 'project', 'plan', 'potential', 'may', 'should', 'expect', 'pending' and similar expressions identify forward-looking statements.
The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management's examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure that we will achieve or accomplish these expectations, beliefs or projections.
In addition to these important factors, other important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, the failure to satisfy the conditions to completion of the Merger set forth in the Merger Agreement, the failure to obtain required shareholder approvals, the failure to complete the Merger within the expected timeframe or at all, the potential for the Merger Agreement to be terminated in accordance with its terms, the exercise of appraisal rights by Golden Ocean shareholders, the potential for litigation in connection with the Merger, the failure of counterparties to fully perform their contracts with us, the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand for dry bulk and tanker vessel capacity, changes in our operating expenses, including bunker prices, dry-docking and insurance costs, the market for our vessels, availability of financing and refinancing, charter counterparty performance, ability to obtain financing and comply with covenants in such financing arrangements, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, general domestic and international political conditions, potential disruption of shipping routes due to accidents or political events, vessels breakdowns and instances of off-hires and other factors. Please see our filings with the United States Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties.
You are cautioned not to place undue reliance on CMB.TECH's forward-looking statements. These forward-looking statements are and will be based upon management's then-current views and assumptions regarding future events and operating performance and are applicable only as of the dates of such statements. CMB.TECH assumes no duty to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date.
Disclaimer
This press release is also published in Dutch. If ambiguities should arise from the different language versions, the English version will prevail.
Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. Persons distributing this communication must satisfy themselves that it is lawful to do so. The potential transactions described in this announcement and the distribution of this announcement and other information in connection with the potential transactions in certain jurisdictions may be restricted by law and persons into whose possession this announcement, any document or other information referred to herein comes should inform themselves about, and observe, any such restrictions.
This announcement is not a recommendation in favor of the proposed Merger described herein. In connection with the proposed Merger, CMB.TECH has filed with the SEC the Registration Statement that includes a prospectus of CMB.TECH and a proxy statement of Golden Ocean. CMB.TECH also has filed other relevant documents with the SEC regarding the proposed Merger. YOU ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE MERGER AND RELATED MATTERS. You may obtain a free copy of the proxy statement/prospectus and other relevant documents that CMB.TECH files with the SEC at the SEC's website at www.sec.gov.
Attachment
Katrien Hennin CMB.TECH +32 499393470 [email protected]
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

1 Reason to Buy Berkshire Hathaway (BRK.A) Stock
1 Reason to Buy Berkshire Hathaway (BRK.A) Stock

Yahoo

time14 minutes ago

  • Yahoo

1 Reason to Buy Berkshire Hathaway (BRK.A) Stock

Key Points CEO Warren Buffett has helped make Berkshire Hathaway one of the world's most successful companies. Berkshire Hathaway has actually significantly underperformed the S&P 500 index this year, but the stock looks like a smart long-term play. Berkshire's massive cash pile and proven team of leaders and analysts makes the stock a worthwhile investment. 10 stocks we like better than Berkshire Hathaway › Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) is one of the world's largest and most successful companies. Led by visionary investor and CEO Warren Buffett since 1965, the investment conglomerate has a market capitalization of roughly $995 billion -- and it ranks as the 11th-largest overall business in the world. Buffett has been an incredible leader for the company and helped it to crush the broader market over the last half century, but he's poised to step down as the company's CEO at the end of this year. Board chairman Greg Abel will be succeeding Buffett in the CEO role -- a passing of the torch that will mark one of the most high-profile leadership transitions in finance history. While Buffett's move out of the CEO role could create some uncertainty for the stock heading into next year, the company has a great team of analysts and seems to have a strong succession plan in place. Even with a key management transition on the near horizon, there's a great reason to buy Berkshire Hathaway stock right now. Berkshire Hathaway stock looks like a smart defensive investment Berkshire stock has gained roughly 2% year to date as of this writing -- a performance that lags significantly behind the S&P 500 index's gain of roughly 8%. Some of the reasoning for the relative underperformance is relatively clear. Berkshire has been a substantial net seller of stocks over the last year and opted to stay on the sidelines as some growth-dependent plays have seen huge valuation gains and helped push major indexes to new record levels. While this has meant that Buffett's company has missed out on some of the effects of the market's recent rally, it also makes the investment conglomerate's stock more appealing as a defensive play right now. Berkshire has a fantastic team of stock pickers, and the company has amassed a $344 billion cash pile that it will deploy when the team thinks bargains are available. For long-term investors, Berkshire continues to have the makings of a portfolio anchor with market-beating potential. Should you buy stock in Berkshire Hathaway right now? Before you buy stock in Berkshire Hathaway, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Berkshire Hathaway wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway. The Motley Fool has a disclosure policy. 1 Reason to Buy Berkshire Hathaway (BRK.A) Stock was originally published by The Motley Fool

Global Market to Reach $129.1 Billion by 2030 - Rising Infectious Diseases, Technological Advancements, and Pandemic Preparedness Drive Growth
Global Market to Reach $129.1 Billion by 2030 - Rising Infectious Diseases, Technological Advancements, and Pandemic Preparedness Drive Growth

Yahoo

time14 minutes ago

  • Yahoo

Global Market to Reach $129.1 Billion by 2030 - Rising Infectious Diseases, Technological Advancements, and Pandemic Preparedness Drive Growth

Dublin, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The "mRNA Platform - Global Strategic Business Report" report has been added to global market for mRNA Platform was estimated at US$152.0 Billion in 2024 and is projected to reach US$129.1 Billion by 2030, growing at a CAGR of -2.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business mRNA platform has emerged as a groundbreaking innovation in the field of biotechnology and pharmaceuticals, revolutionizing the way vaccines and therapeutics are developed and deployed. mRNA, or messenger RNA, acts as a blueprint for protein synthesis within cells, and this technology harnesses that mechanism to instruct cells to produce specific proteins that can trigger an immune response or treat diseases. The success of mRNA-based COVID-19 vaccines, developed by companies like Moderna and Pfizer-BioNTech, has showcased the platform`s potential for rapid and scalable vaccine production. Unlike traditional vaccines, which often require months or years to develop, mRNA vaccines can be designed and manufactured much more quickly, providing a crucial tool in responding to emerging infectious advancements have significantly enhanced the capabilities and applications of the mRNA platform. Innovations in lipid nanoparticle (LNP) delivery systems have improved the stability and efficiency of mRNA molecules, allowing for effective delivery into cells. This has broadened the potential applications of mRNA technology beyond vaccines to include treatments for cancer, genetic disorders, and other diseases. The flexibility of the mRNA platform allows for the rapid redesign of vaccines and therapeutics to address new virus variants or different diseases, making it a versatile tool in precision medicine. Additionally, advancements in synthetic biology and bioinformatics have enabled more precise and efficient mRNA sequence design, optimizing the expression and effectiveness of the encoded growth in the mRNA platform market is driven by several factors, including the increasing incidence of infectious diseases, advancements in mRNA technology, and significant investments in biotechnology research. The ongoing threat of pandemics and the need for swift and effective responses have highlighted the importance of mRNA vaccines, spurring demand and investment in this technology. Technological advancements, such as improved delivery systems and more efficient manufacturing processes, have enhanced the scalability and efficacy of mRNA-based products. Furthermore, substantial investments from both public and private sectors are accelerating research and development activities, leading to new therapeutic applications and expanding the market potential. Regulatory support and expedited approval processes for mRNA vaccines and therapies have also contributed to the rapid growth of this market. These factors collectively underscore the transformative impact of the mRNA platform in modern medicine and its potential to address a wide range of health challenges. Key Insights: Market Growth: Understand the significant growth trajectory of the COVID-19 Vaccine segment, which is expected to reach US$102.1 Billion by 2030 with a CAGR of a -6.3%. The Cancer Vaccine segment is also set to grow at 86.1% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $64.5 Billion in 2024, and China, forecasted to grow at an impressive 0.1% CAGR to reach $13.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as AstraZeneca PLC, Asuragen, Inc., Catalent Pharma Solutions, Altogen Labs, Arcturus Therapeutics, Inc. and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Scope Segments:Indication (COVID-19 Vaccine, Cancer Vaccine, Other Indications) Geographic Regions/Countries:World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World. Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns mRNA Platform - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MRNA - A CONCEPTUAL UNDERSTANDING MRNA: A New Approach to Medicine Long Wait & Scientific Breakthroughs mRNA Vaccines - An Introduction With Unparalleled Turnaround Time, mRNA Platform Adds Revolutionary Dimension to Vaccine Development mRNA: Making Cells Act as Vaccine Factory mRNA Vaccines: Advantages mRNA Vaccines: Cons mRNA Vaccine Approvals A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine Traditional Vs. mRNA Vaccines: Key Differences Traditional Vs. mRNA Vaccines: The Development Process How mRNA Vaccine Works & Earlier Testing Efforts mRNA Vaccines: Safety Quotient Other Notable Efforts Centered on mRNA Technology Overcoming Challenges As Serious Candidate, mRNA Technology Warrants Attention from Scientific Community GLOBAL MARKET OVERVIEW Global mRNA Vaccines Market on a Dynamic Growth Track mRNA Vaccines Could Vanquish Cancer and Other Diseases, Cancer Segment to Make Major Contribution to Global mRNA Vaccines Market The US Holds Leading Position, while Asia-Pacific Exhibits Lucrative Growth in mRNA Vaccines Market Faster, Effective and Cheaper: Adaptability of mRNA Vaccine Unleashes Potential Utility for Developing Nations RECENT MARKET ACTIVITY IN THE COVID-19 VACCINE SPACE Pfizer and BioNTech's COVID-19 Vaccine Receives World's First Authorization UK Clinches the First Position in the World to Approve Pfizer's Vaccine After UK, US Gives Nod to Pfizer's Vaccine EU Approves Pfizer's Vaccine BioNTech to Scale up Vaccine Production to Fill Supply Gaps and Support Vaccination Efforts in the EU Novartis Inks Agreement with Pfizer-BioNtech to Support COVID-19 Vaccine Production FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021) Moderna's mRNA Vaccine Bags Approval from US FDA Moderna Kick-Starts Inoculation in the US FDA Approves Pfizer-BioNTech Vaccine in Kids aged 12 to 15 Years Age (May, 2021) Moderna Begins Testing its Vaccine on Children Aged Below 12 Years (March, 2021) Recent Market Activity COMPETITIVE SCENARIO BioNTech - A Pioneer in mRNA-based Vaccines and Therapies List of BioNTech's mRNA Candidates in Clinical Trials for Cancer Moderna's Ambitious Stride into Vaccine Development: From a Novice to Know All Moderna's mRNA Prophylactic Vaccines mRNA Cancer Vaccines mRNA Intratumoral Immuno-Oncology mRNA Systemic Secreted & Cell Surface Therapeutics mRNA Systemic Intracellular Therapeutics mRNA as Promising Vaccine Technology Entices Startups to Join the Bandwagon Noteworthy Startups Exploiting mRNA Technology Providence Therapeutics pHion Therapeutics eTheRNA immunotherapies & 20Med Therapeutics MARKET TRENDS & DRIVERS Increasing Prevalence of Infectious & Chronic Conditions to Unleash Gains & Help mRNA Vaccines Market Gallop Ahead mRNA Vaccines Development for Other Infectious Diseases and Therapeutic Areas Gains Momentum Worldwide Cancer Incidence: Number of New Cancer Cases Diagnosed for 2012, 2018 & 2040 Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for the Market Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030 Increasing Healthcare Expenditure to Foster Market Growth Consistent Increase in Risks and Threats from Infections Drive Healthy Market Growth Global Number of Deaths Caused Due to Communicable Diseases (In 000s) Regulatory Landscape for mRNA Vaccines Regulatory Pathway Dealing with mRNA Vaccines mRNA Vaccine Patent Scenario The Best Route of Administration for mRNA Vaccines mRNA CANCER VACCINES Introduction Cancer Vaccines Vs. Immunotherapies Clinical Trials of mRNA Encoding Immunostimulants mRNA Vaccines Vs. DNA Vaccines Clinical Trials of mRNA Encoding TAAs mRNA Vaccines Vs. Other Vaccines Clinical Trials of mRNA Vaccines Encoding Neoantigens (Neo-Ag) mRNA Benefits Profile mRNA Vaccines for COVID-19 Pave the Way Challenges Personalized mRNA Vaccine Clinical Overview of mRNA Cancer Vaccines mRNA encoding Immunostimulants mRNA vaccine encoding tumor-associated antigens mRNA vaccine encoding Neoantigen, personalized vaccine mRNA Influenza Vaccines Perpetual Evolution of Influenza Viruses Makes mRNA a Fascinating Vaccine Platform Vaccines Built on mRNA Clinical Trials for mRNA Vaccines mRNA Vaccine as Game Changer for Flu Viruses Eluding Conventional Vaccine Efforts mRNA: A Next-Generation Vaccination Approach Moderna Moves Ahead to Brew Novel mRNA Vaccines for Influenza & Other Viruses COVID-19 Vaccine Technology to Foster Development of Effective Flu Shots mRNA Vaccines Vs. Other Flu Shots mRNA Technology, H/N Spike Proteins & Clinical Trials mRNA Technology: A Suitable Candidate for Universal & Effective Influenza Vaccines Benefits & Limitations of mRNA Vaccines over Traditional Options FOCUS ON SELECT PLAYERS |Some of the 96 companies featured in this report AstraZeneca PLC Asuragen, Inc. Catalent Pharma Solutions Altogen Labs Arcturus Therapeutics, Inc. BioNTech AG CRISPR Therapeutics Aldevron AKESOgen, Inc. baseclick GmbH chimeron bio Acuitas Therapeutics Accent Therapeutics Accanis Biotech F&E GmbH & Co KG Avectas For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Magna to Showcase Its Vision for Safer, Smarter, Greener Mobility at IAA Mobility 2025
Magna to Showcase Its Vision for Safer, Smarter, Greener Mobility at IAA Mobility 2025

Yahoo

time14 minutes ago

  • Yahoo

Magna to Showcase Its Vision for Safer, Smarter, Greener Mobility at IAA Mobility 2025

Magna IAA Mobility 2025 Discover Magna's broad portfolio of sustainable materials, drivetrains and energy storage systems at IAA Mobility Hall B3, Booth E40 Experience outdoor live vehicle demos and expert insights into Magna's latest Radar Technologies and Interior Sensing Systems Explore the latest breakthroughs in occupant monitoring, sensor fusion and AI-powered decision-making SAILAUF, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Magna, one of the world's largest and most trusted suppliers in the automotive industry, will showcase the latest innovations shaping mobility today and in the future at IAA Mobility 2025, in Munich. From September 8 to 14, the company will present advancements in sustainable materials, drivetrain technologies, energy storage systems and Advanced Driver Assistance Systems at Hall B3, Booth E40. Visitors to the Magna booth will experience how the company is shaping the future of mobility with its innovative solutions that minimize environmental impact, conserve resources and support social and economic development. A key focus will be on sustainable materials that meet the highest technical standards while reducing the ecological footprint of vehicles. 'IAA Mobility is a key platform for Magna to demonstrate how our innovations are driving real-world change – from sustainable materials and flexible powertrain solutions to intelligent driving technologies,' said Uwe Geissinger, Executive Vice President and President Magna Europe. 'We're not just showcasing concepts; we're delivering scalable solutions that help our customers navigate the shift to safer, smarter and greener mobility today.' Magna will also present its flexible powertrain systems designed to meet the needs of diverse vehicle segments. Advanced battery-integrated body and chassis systems, along with modular energy storage solutions, will be introduced to support the electrification of transportation with greater efficiency and reliability. Additionally, the exhibition will feature Magna's latest technologies for Level 2+ and 3 driving systems, including intelligent sensor fusion, AI-powered decision-making processes with robust safety architectures. Live vehicle demonstrations will showcase innovations in imaging radar, radar fusion and interior sensing technologies — all critical for enhancing vehicle perception, occupant monitoring and overall driving safety. Customers can schedule outdoor demo drives by registering at the Magna booth. Magna's presence at IAA Mobility 2025 highlights its commitment to delivering real-world solutions that move the industry forward. To stay up to date with Magna's latest IAA news, visit or follow the company on social media. INVESTOR CONTACT Louis Tonelli, Vice President, Investor Relations │ (+1) 905.726.7035 MEDIA CONTACT Tracy Fuerst, Vice President, Corporate Communications & │ (+1) 248.761.7004 Rej Husetovic, Director Corporate Communications │ (+49) 6093.9942.5056 ABOUT MAGNA INTERNATIONALMagna is more than one of the world's largest suppliers in the automotive space. We are a mobility technology company built to innovate, with a global, entrepreneurial-minded team of approximately 164,000 employees across 338 manufacturing operations and 106 product development, engineering and sales centres spanning 28 countries. With 65+ years of expertise, our ecosystem of interconnected products combined with our complete vehicle expertise uniquely positions us to advance mobility in an expanded transportation landscape. For further information about Magna (NYSE:MGA; TSX:MG), please visit or follow us on social. THIS RELEASE MAY CONTAIN STATEMENTS WHICH CONSTITUTE 'FORWARD-LOOKING STATEMENTS' UNDER APPLICABLE SECURITIES LEGISLATION AND ARE SUBJECT TO, AND EXPRESSLY QUALIFIED BY, THE CAUTIONARY DISCLAIMERS THAT ARE SET OUT IN MAGNA'S REGULATORY FILINGS. PLEASE REFER TO MAGNA'S MOST CURRENT MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL POSITION, ANNUAL INFORMATION FORM AND ANNUAL REPORT ON FORM 40-F, AS REPLACED OR UPDATED BY ANY OF MAGNA'S SUBSEQUENT REGULATORY FILINGS, WHICH SET OUT THE CAUTIONARY DISCLAIMERS, INCLUDING THE RISK FACTORS THAT COULD CAUSE ACTUAL EVENTS TO DIFFER MATERIALLY FROM THOSE INDICATED BY SUCH FORWARD-LOOKING STATEMENTS. THESE DOCUMENTS ARE AVAILABLE FOR REVIEW ON MAGNA'S WEBSITE AT A photo accompanying this announcement is available at while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store